Edition:
India

Albireo Pharma Inc (ALBO.OQ)

ALBO.OQ on NASDAQ Stock Exchange Capital Market

34.53USD
16 Feb 2018
Change (% chg)

$-1.06 (-2.98%)
Prev Close
$35.59
Open
$35.28
Day's High
$35.50
Day's Low
$34.45
Volume
10,474
Avg. Vol
13,273
52-wk High
$39.67
52-wk Low
$15.31

Select another date:

Thu, Jan 25 2018

BRIEF-Albireo Prices $65.0 Mln Public Offering Of Common Stock

* ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation

* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS

BRIEF-Albireo Announces Agreement With Healthcare Royalty Partners

* ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN

BRIEF-Albireo posts Q3 loss per share $0.73‍​

* Albireo Pharma Inc - ‍decision on potential approval of elobixibat in Japan expected in first half of 2018​

BRIEF-Albireo Pharma to present final results of phase 2 study of A4250 in children with cholestatic liver disease

* Final results of Albireo’s phase 2 study of A4250 in children with cholestatic liver disease presented at the liver meeting 2017

BRIEF-Albireo Pharma files for mixed shelf of up to $125 million‍​

* Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing‍​ ‍​ Source text for Eikon: (http://bit.ly/2i8yKC7) Further company coverage:

BRIEF-Albireo elects Roger Jeffs to board of directors

* Albireo Pharma Inc - ‍Jeffs replaces Denise Scots-Knight, who is departing from board​ Source text for Eikon: Further company coverage:

BRIEF-EMA paediatric committee agrees to Albireo's A4250 pediatric investigation plan

* EMA's paediatric committee agrees to Albireo’s a4250 pediatric investigation plan

BRIEF-Albireo Pharma Q2 loss per share $0.86

* Albireo Pharma Inc - qtrly net loss per share diluted $0.86

Select another date: